MedTrace Logo

Carboprost (Hemabate) for Fibroid Resection

NCT05518812 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2024-09-19

No results posted yet for this study

Summary

The purpose of this research study is to determine if low-dose (i.e., a fraction of what is commonly used) carboprost (Hemabate) helps facilitate fibroid removal (myomectomy).

Conditions

  • Fibroid Uterus
  • Gynecologic Disease
  • Leiomyoma, Uterine

Interventions

DRUG

Carboprost Tromethamine

During myomectomy, low-dose carboprost will be injected at the base of the fibroid and repeated as necessary. The efficacy of low-dose carboprost is being assessed, and the total dose administered will not exceed single vial for other indications.

Sponsors & Collaborators

Principal Investigators

  • Magdy p Milad, MD, MS · Northwestern University, Northwestern Memorial Hopsital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-12
Primary Completion
2024-05-06
Completion
2024-05-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05518812 on ClinicalTrials.gov